Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary AngioedemaGlobeNewsWire • 03/21/23
Intellia Therapeutics: Progressing Pipeline Signals Positive Outlook For InvestorsSeeking Alpha • 03/08/23
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene EditingInvestors Business Daily • 03/02/23
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)GlobeNewsWire • 03/02/23
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 02/23/23
Is Intellia Therapeutics (NTLA) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 02/22/23
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 02/16/23
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company UpdatesGlobeNewsWire • 02/16/23